Compare $NNVC vs $RNAZ | Chartloom

Compare

$NNVC vs $RNAZ

NanoViricides, Inc · Transcode Therapeutics Inc

NNVC

NanoViricides, Inc

RNAZ

Transcode Therapeutics Inc

Compare $NNVC vs $RNAZ

Comparing NanoViricides, Inc and Transcode Therapeutics Inc

NNVCNanoViricides, Inc

RNAZTranscode Therapeutics Inc

NNVCNanoViricides, Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

7.4%

52W performance

-9.1%

FCF yield

-23.6%

RNAZTranscode Therapeutics Inc

Market cap

$2M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.9%

52W performance

-82.4%

FCF yield

-1146.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NNVC

RNAZ

Detailed metrics comparison

NNVC

NanoViricides, Inc

RNAZ

Transcode Therapeutics Inc

Market Cap

NNVC$33M

RNAZ$2M

Enterprise Value

NNVC$30M

RNAZ$-6M

Price

NNVC$1.30

RNAZ$1.86

P/E Ratio

NNVCN/A

RNAZN/A

P/S Ratio

NNVC0.00x

RNAZ0.00x

EV/Sales

NNVC0.00x

RNAZ0.00x

EV/EBITDA

NNVC0.00x

RNAZ0.00x

P/B Ratio

NNVC3.76x

RNAZ0.19x

P/FCF Ratio

NNVCN/A

RNAZN/A

EV/FCF

NNVC-3.88x

RNAZ0.25x

PEG Ratio

NNVCN/A

RNAZN/A

Forward P/E (NTM)

NNVCN/A

RNAZN/A

Forward P/S (NTM)

NNVCN/A

RNAZN/A

Revenue (TTM)

NNVC$0

RNAZ$0

Revenue Growth (YoY)

NNVCN/A

RNAZN/A

Forward Rev Growth

NNVC0.0%

RNAZ0.0%

Gross Margin (TTM)

NNVC0.0%

RNAZ0.0%

Operating Margin (TTM)

NNVC0.0%

RNAZ0.0%

EBITDA Margin (TTM)

NNVC0.0%

RNAZ0.0%

Net Margin (TTM)

NNVC0.0%

RNAZ0.0%

FCF Margin (TTM)

NNVCN/A

RNAZN/A

Net Income (TTM)

NNVC$-8M

RNAZ$-46M

FCF (TTM)

NNVC$-8M

RNAZ$-23M

EPS (TTM)

NNVC-$0.37

RNAZ-$48.35

ROE (TTM)

NNVC-9111.0%

RNAZ-3928.0%

ROA (TTM)

NNVC-8074.0%

RNAZ-3601.0%

ROIC (TTM)

NNVC-9111.0%

RNAZ-3922.0%

Cash

NNVC$3M

RNAZ$8M

Debt

NNVC$0

RNAZ$652K

Net Cash/Debt

NNVC$3M

RNAZ$8M

Current Ratio (TTM)

NNVC2.66x

RNAZ1.97x

Quick Ratio (TTM)

NNVC2.35x

RNAZ1.55x

Debt/Equity (TTM)

NNVC0.00x

RNAZ0.00x

Debt/Assets (TTM)

NNVC0.0%

RNAZ0.0%

Interest Coverage (TTM)

NNVCN/A

RNAZN/A

Net Debt/EBITDA (TTM)

NNVC0.00x

RNAZ0.00x

Beta

NNVC1.91

RNAZ1.29

52W Performance

NNVC-9.1%

RNAZ-82.4%

YTD Performance

NNVC7.4%

RNAZ-74.9%

% from 52W High

NNVC-41.7%

RNAZ-91.1%

% from 52W Low

NNVC52.9%

RNAZ22.4%

Asset Turnover (TTM)

NNVC0.00x

RNAZ0.00x

FCF Yield (TTM)

NNVC-23.6%

RNAZ-1146.9%

Earnings Yield (TTM)

NNVC-24.9%

RNAZ-2347.6%

Dividend Yield (TTM)

NNVCN/A

RNAZN/A

Rule of 40

NNVC0.0

RNAZ0.0

EV/GP/RG

NNVCN/A

RNAZN/A

Ticker research

View NNVC research View RNAZ research

Metric	NNVC NanoViricides, Inc	RNAZ Transcode Therapeutics Inc
Market & Valuation
Market Cap	$33M	$2M
Enterprise Value	$30M	$-6M
Price	$1.30	$1.86
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.76x	0.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.88x	0.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-46M
FCF (TTM)	$-8M	$-23M
EPS (TTM)	-$0.37	-$48.35
ROE (TTM)	-9111.0%	-3928.0%
ROA (TTM)	-8074.0%	-3601.0%
ROIC (TTM)	-9111.0%	-3922.0%
Financial Health
Cash	$3M	$8M
Debt	$0	$652K
Net Cash/Debt	$3M	$8M
Current Ratio (TTM)	2.66x	1.97x
Quick Ratio (TTM)	2.35x	1.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.91	1.29
52W Performance	-9.1%	-82.4%
YTD Performance	7.4%	-74.9%
% from 52W High	-41.7%	-91.1%
% from 52W Low	52.9%	22.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-23.6%	-1146.9%
Earnings Yield (TTM)	-24.9%	-2347.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NNVC research	View RNAZ research

Valuation

P/S Ratio

NNVC

0.00x

RNAZ

0.00x

EV/FCF

NNVC

-3.88x

RNAZ

0.25x

Growth & revenue

Forward Revenue Growth

NNVC

0.0%

RNAZ

0.0%

Profitability & performance

Gross Margin

NNVC

0.0%

RNAZ

0.0%

ROE

RNAZ

-3928.0%

NNVC

-9111.0%

FCF Yield %

NNVC

-23.6%

RNAZ

-1146.9%

52-Week Performance

NNVC

-9.1%

RNAZ

-82.4%

Detailed metrics comparison

NNVC

NanoViricides, Inc

RNAZ

Transcode Therapeutics Inc

Market Cap

NNVC$33M

RNAZ$2M

Enterprise Value

NNVC$30M

RNAZ$-6M

Price

NNVC$1.30

RNAZ$1.86

P/E Ratio

NNVCN/A

RNAZN/A

P/S Ratio

NNVC0.00x

RNAZ0.00x

EV/Sales

NNVC0.00x

RNAZ0.00x

EV/EBITDA

NNVC0.00x

RNAZ0.00x

P/B Ratio

NNVC3.76x

RNAZ0.19x

P/FCF Ratio

NNVCN/A

RNAZN/A

EV/FCF

NNVC-3.88x

RNAZ0.25x

PEG Ratio

NNVCN/A

RNAZN/A

Forward P/E (NTM)

NNVCN/A

RNAZN/A

Forward P/S (NTM)

NNVCN/A

RNAZN/A

Revenue (TTM)

NNVC$0

RNAZ$0

Revenue Growth (YoY)

NNVCN/A

RNAZN/A

Forward Rev Growth

NNVC0.0%

RNAZ0.0%

Gross Margin (TTM)

NNVC0.0%

RNAZ0.0%

Operating Margin (TTM)

NNVC0.0%

RNAZ0.0%

EBITDA Margin (TTM)

NNVC0.0%

RNAZ0.0%

Net Margin (TTM)

NNVC0.0%

RNAZ0.0%

FCF Margin (TTM)

NNVCN/A

RNAZN/A

Net Income (TTM)

NNVC$-8M

RNAZ$-46M

FCF (TTM)

NNVC$-8M

RNAZ$-23M

EPS (TTM)

NNVC-$0.37

RNAZ-$48.35

ROE (TTM)

NNVC-9111.0%

RNAZ-3928.0%

ROA (TTM)

NNVC-8074.0%

RNAZ-3601.0%

ROIC (TTM)

NNVC-9111.0%

RNAZ-3922.0%

Cash

NNVC$3M

RNAZ$8M

Debt

NNVC$0

RNAZ$652K

Net Cash/Debt

NNVC$3M

RNAZ$8M

Current Ratio (TTM)

NNVC2.66x

RNAZ1.97x

Quick Ratio (TTM)

NNVC2.35x

RNAZ1.55x

Debt/Equity (TTM)

NNVC0.00x

RNAZ0.00x

Debt/Assets (TTM)

NNVC0.0%

RNAZ0.0%

Interest Coverage (TTM)

NNVCN/A

RNAZN/A

Net Debt/EBITDA (TTM)

NNVC0.00x

RNAZ0.00x

Beta

NNVC1.91

RNAZ1.29

52W Performance

NNVC-9.1%

RNAZ-82.4%

YTD Performance

NNVC7.4%

RNAZ-74.9%

% from 52W High

NNVC-41.7%

RNAZ-91.1%

% from 52W Low

NNVC52.9%

RNAZ22.4%

Asset Turnover (TTM)

NNVC0.00x

RNAZ0.00x

FCF Yield (TTM)

NNVC-23.6%

RNAZ-1146.9%

Earnings Yield (TTM)

NNVC-24.9%

RNAZ-2347.6%

Dividend Yield (TTM)

NNVCN/A

RNAZN/A

Rule of 40

NNVC0.0

RNAZ0.0

EV/GP/RG

NNVCN/A

RNAZN/A

Ticker research

View NNVC research View RNAZ research

Metric	NNVC NanoViricides, Inc	RNAZ Transcode Therapeutics Inc
Market & Valuation
Market Cap	$33M	$2M
Enterprise Value	$30M	$-6M
Price	$1.30	$1.86
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.76x	0.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.88x	0.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-46M
FCF (TTM)	$-8M	$-23M
EPS (TTM)	-$0.37	-$48.35
ROE (TTM)	-9111.0%	-3928.0%
ROA (TTM)	-8074.0%	-3601.0%
ROIC (TTM)	-9111.0%	-3922.0%
Financial Health
Cash	$3M	$8M
Debt	$0	$652K
Net Cash/Debt	$3M	$8M
Current Ratio (TTM)	2.66x	1.97x
Quick Ratio (TTM)	2.35x	1.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.91	1.29
52W Performance	-9.1%	-82.4%
YTD Performance	7.4%	-74.9%
% from 52W High	-41.7%	-91.1%
% from 52W Low	52.9%	22.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-23.6%	-1146.9%
Earnings Yield (TTM)	-24.9%	-2347.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NNVC research	View RNAZ research